Will 10x Genomics' (TXG) Flex Assay Shift the Balance Between Innovation and Revenue Stability?

• 10x Genomics recently reported third quarter results showing a slightly lower year-over-year revenue of US$149 million and reduced net loss, and also announced the launch of its next-generation, automation-compatible Flex assay for scalable single cell analysis.
• The company's guidance for fourth quarter 2025 points to a 6% revenue decline year-over-year but sequential growth, highlighting both persistent market headwinds and renewed product innovation.
• With the launch of an automation-friendly Flex assay, we'll explore how this moves the needle in 10x Genomics' investment narrative.

These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

10x Genomics Investment Narrative Recap

To own shares in 10x Genomics, you need to believe in the long-term growth of single-cell and spatial genomics, and the company's ability to lead with innovative, cost-effective solutions. The recent Q3 earnings and cautious Q4 guidance reinforce ongoing market headwinds as a core short-term risk, while product launches remain the key catalyst; these results do not meaningfully change the overall risk/reward balance for now. The launch of the automation-compatible Flex assay stands out, as it could address adoption barriers for high-throughput research and help offset some near-term revenue pressures, supporting the catalyst of driving higher reaction volumes through scalable solutions. But with funding constraints and pricing pressures still front and center, investors should be aware of how...

Read the full narrative on 10x Genomics (it's free!)

10x Genomics' narrative projects $688.4 million revenue and $97.8 million earnings by 2028. This requires 2.2% yearly revenue growth and a $182.4 million increase in earnings from -$84.6 million today.

Uncover how 10x Genomics' forecasts yield a $15.86 fair value, a 4% downside to its current price.

Exploring Other Perspectives

Six member opinions from the Simply Wall St Community value 10x Genomics between US$6.47 and US$23.59 per share. Persistent academic funding uncertainty remains a key risk that could impact future revenue and margins, so consider a wide spectrum of forecasts and analysis.

Explore 6 other fair value estimates on 10x Genomics - why the stock might be worth as much as 42% more than the current price!

Build Your Own 10x Genomics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your 10x Genomics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free 10x Genomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate 10x Genomics' overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Rare earth metals are the new gold rush. Find out which 37 stocks are leading the charge.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• We've found 15 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com